In cancer, personalized medicine takes advantage of the unique genetic changes in an individual tumor to find its vulnerabilities and fight it. Many tumors have a higher number of mutations due to a antiviral defense mechanism, the APOBEC system, which can accidentally damage DNA and cause mutations.
Researchers at IRB Barcelona led by Dr. Travis Stracker and Dr. Fran Supek have found the HMCES enzyme to be the Achilles heel of some lung tumors, specifically those with a higher number of mutations caused by the APOBEC system.
“We have discovered that blocking HMCES is very damaging to cells with an activated APOBEC system (which are many lung cancer cells), but much less so for those in which it is not activated (as is often the case in healthy cells),” explains Dr. Supek, ICREA researcher and head of the Genome Data Science lab at IRB Barcelona.
“Besides showing specificity to cancer cells, HMCES is potentially targetable by drugs, which makes it a great candidate for future lung cancer treatments,” adds Dr. Stracker, former group leader at IRB Barcelona, now working at the National Cancer Institute (NIH/NCI) in the U.S..
A multidisciplinary approach to double-check the best strategy
Involving collaboration between two research groups working on different disciplines, the study comprised both a computational and experimental approach. Genetic screening experiments were performed using CRISPR/Cas9 on several types of human lung adenocarcinoma cell lines. “These experiments can interrogate the effects of removing each gene individually from the cancer cells and they allow us to see whether the cancer can tolerate this change,” say Josep Biayna and Isabel Garcia Cao, IRB Barcelona researchers and first and second authors of the article. Previous data from CRISPR genetic screens performed by other labs were also statistically analyzed and confirmed the experimental results.
A mutation fog caused by a defense system
When cells sense a mismatch in their DNA, they undergo a DNA repair reaction to preserve genetic information. Remarkably, this reaction can become coupled to the APOBEC enzymes, typically used by human cells to defend against viruses and having an important role in fighting hepatitis and HIV. This mechanism was previously described by the Genome Data Science lab and indicates that, in some cases, when the APOBEC enzymes and the DNA repair process are simultaneously active, APOBEC hijacks DNA repair, thus generating the mutation fog.
Outsmarting cancer evolution
Late-stage cancers can accumulate a high number of mutations in their DNA, which can cause the cancer to become more aggressive or to resist drugs better. Many of these mutations may be caused by APOBEC which accelerates tumor evolution. Therefore, killing cancer cells that activate APOBEC should slow down tumor evolution and prevent it from gaining new dangerous mutations.
Scientists discover that a normal DNA repair process can become a major source of mutations in cancer
Josep Biayna et al. Loss of HMCES is synthetic lethal with APOBEC activity in cancer cells, (2021). DOI: 10.1101/2021.02.05.429803
Scientists identify a potential target to treat lung cancer (2021, April 7)
retrieved 7 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022